CN105998198A - Health product for improving hyperlipidemia, hyperglycemia and hypertension and preparation method thereof - Google Patents
Health product for improving hyperlipidemia, hyperglycemia and hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN105998198A CN105998198A CN201610622457.5A CN201610622457A CN105998198A CN 105998198 A CN105998198 A CN 105998198A CN 201610622457 A CN201610622457 A CN 201610622457A CN 105998198 A CN105998198 A CN 105998198A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- capsule
- health product
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036541 health Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract description 9
- 206010020772 Hypertension Diseases 0.000 title abstract description 7
- 201000001421 hyperglycemia Diseases 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 47
- 210000000582 semen Anatomy 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims description 36
- 239000002775 capsule Substances 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007902 hard capsule Substances 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920005479 Lucite® Polymers 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- -1 hydroxylmethyl Chemical group 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 13
- 239000008103 glucose Substances 0.000 abstract description 13
- 230000036772 blood pressure Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 244000046146 Pueraria lobata Species 0.000 abstract description 3
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 2
- 235000020774 essential nutrients Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000031513 cyst Diseases 0.000 description 6
- 206010011732 Cyst Diseases 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 210000001699 lower leg Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108090000279 Peptidyltransferases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000366676 Justicia pectoralis Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of nutritional health protection, and particularly relates to a health product, as well as a preparation method and application thereof. The health product is prepared from the following components in parts by weight: 48 parts of yeast powder, 40-60 parts of folium mori extract, 30-50 parts of semen cassiae extract, 11 parts of kudzu vine root extract, 12 parts of semen phaseoli extract and 20-35 parts of gynostemma pentaphylla extract. The health product is prepared from edible and medicinal raw materials with effects of tonifying middle warmer and qi, wherein the main components, namely the gynostemma pentaphylla and folium mori, have the effects of reducing blood pressure, blood glucose and blood lipid, and the semen phaseoli, kudzu vine roots, semen cassiae and yeast powder are added to achieve a synergistic effect with the main components. The health product is used for supplying essential nutrients, so that while the symptoms of hyperlipidemia, hyperglycemia and hypertension can be reduced, and complications caused by hyperlipidemia, hyperglycemia and hypertension can be balanced for patients. Furthermore, conventional commercial extracts are adopted in the formula, so that a distilling extraction process is reduced, operation is facilitated, and the product in the formula is low in cost and beneficial to popularization.
Description
Technical field
The present invention relates to nourishing healthy field, be specifically related to one and improve health product and the system thereof of " three-hypers disease "
Preparation Method.
Background technology
" three-hypers disease " refers to hypertension, hyperglycemia (diabetes) and hyperlipidemia.They are institutes of modern society
" affluenza " derived from, possible individualism, it is also possible to interrelated.As: diabetes patient is easy to
Suffer from hypertension or hyperlipidemia simultaneously, and hyperlipidemia be the principal element of arteriosclerosis formation and development,
Arteriosclerotic's blood vessel elasticity difference aggravation blood pressure raises, so the later stage all defines " three-hypers disease ".Relevant system
Meter data shows, in the Chinese ten big causes of death, the mortality rate relevant to metabolic disease is the most up to
35.7%, the death toll relevant to " three high " also accounts for the 27% of total death toll.Hyperlipidemia can cause blood
Pipe thromboembolism；Hypertension can cause cerebral hemorrhage and rupture of blood vessel in brain；Hyperglycemia can cause diabetes.The world
Health organization the most clearly proposes, and prevents the first line of defence of cardiovascular diseases from reducing " three high " and control exactly
" three high ".The clinical improvement to three-hypers, typically now by Western medicine reducing pressure and sugar lipid lowerers, these medicines are general
Side effect is big, the most once takes and just needs to take throughout one's life, it is impossible to reach the purpose for the treatment of both the principal and secondary aspects of a disease, and some
Medicine also has withdrawal reaction, so, how to utilize Basic Theories of Chinese Medicine, in conjunction with the advantage of Chinese crude drug, invention
A kind of evident in efficacy, side effect is little, can solve the alternative tea of problem.
Being prevented and cured diseases by regulation function of human body balance is the characteristic of Chinese medicine.Precious at abundant motherland's medicine
In storehouse, use the Chinese herbal medicine of integration of edible and medicinal herbs that three-hypers disease carries out health care conditioning and there is distinctive feature.Existing market
These type of health product upper are of a great variety, but really play the most little of good result.CN101401601B discloses
A kind of " fall three-hypers (blood being made up of raw materials such as Folium Camelliae sinensis, Folium Ginseng, Folium Apocyni Veneti, Folium Mori, Folium Ginkgo, Ganodermas
Pressure, blood fat, blood glucose) " five leaf celestial being tea, but the rarenesses such as its Ganoderma to be used, Folium Ginseng, expensive raw material,
It is difficult to popularize.And it is known that different Chinese herbal medicine formulas, its health-care effect or conditioning three-hypers
Degree has marked difference.
Summary of the invention
It is an object of the invention to overcome the health care medicine improving three-hypers disease in prior art to be difficult to reducing three-hypers
The shortcoming that while disease, its complication can be played the effect that auxiliary is improved.One is provided to improve " three-hypers disease "
Health product and preparation method thereof.
The technical scheme used by realizing the purpose of the present invention is:
One improves " three-hypers disease " health product, containing following content of component:
Yeast powder 48 parts, Folium Mori extract 40-60 part, Semen Cassiae extract 30 50 parts, Radix Puerariae extracts
Thing 11 parts, Semen Phaseoli extract 12 parts, Herb Gynostemmae Pentaphylli extract 20 35 parts.
As the most preferred,
Containing following content of component: yeast powder 48 parts, Folium Mori extract 50 parts, Semen Cassiae extract 40
Part, Radix Puerariae extract 11 parts, Semen Phaseoli extract 12 parts, Herb Gynostemmae Pentaphylli extract 28 parts.
Described each component presses respective formula ratio, can make hard capsule, tablet, oral solutions, medicinal granules of powder
Or the one in pill.
Employing following step when preparing hard capsule:
1): be ground into powder after the component of described mass parts being stirred, 80 mesh sieves are crossed, with
After starch mix homogeneously, with 10% starch slurry soft material, soft material is crossed 20 mesh sieves and makes wet granular, by wet
Grain and 60-70 DEG C of drying, the dry granule obtained arranges with 20 mesh sieves, obtains drug particles；
2): the capsule board using lucite to support is filled, and first capsule cap, capsule status is opened；Capsule body inserts glue
In capsule plate holes, the distance of regulation levels, make capsule mouth equal with plate face.By step 1) granule that obtains
Be laid on plate face, vibration capsule board gently, make particles filled uniformly.After filling up each capsule, by plate face
Unnecessary granule cleaning, jack-up capsule body, set and capsule cap, take out capsule, to obtain final product.
Employing following step when preparing medicinal granules of powder:
1) it is ground into powder after the component of described mass parts being stirred, crosses 120 mesh sieves standby；
2) by sweeting agent 0.02-1 part, stabilizer 0.1～1 part are together with step 1) powder that obtains adds stirring
After stirring in trough cross 16 mesh stainless (steel) wires pelletize, dry, powdered agent；
Described sweeting agent is the one in aspartame, neotame, sucralose, stevioside, acesulfame potassium or several
The mixture planted；Described stabilizer is sodium alginate, xanthan gum, carrageenan, pectin, hydroxylmethyl cellulose
The mixing of one or more in element sodium, guar gum, gellan gum, arabic gum, locust bean gum or chitin
Thing.
Compared with prior art, the invention has the beneficial effects as follows:
Effect of each component in inventive formulation:
Folium Mori have the effects such as blood pressure lowering, blood fat, antiinflammatory.It is demonstrated experimentally that the ecdysterone pair contained by Folium Mori
The blood glucose of multiple method induction raises all blood sugar reducing function, can promote that glucose is converted into glycogen, but not change
The blood glucose of intact animal.
Semen Cassiae, is leguminous plant Semen Cassiae or the dry mature seed of little Semen Cassiae, has the merit of improving eyesight and name with it
It.Gather autumn mature fruit, dry, lay seed, remove impurity.It is Semen Cassiae bitter in the mouth, sweet, salty,
Cold nature, enters liver, kidney, large intestine channel；Loosening bowel to relieve constipation, blood fat reducing improving eyesight, improves constipation and hyperlipidemia, high blood
Pressure.Liver heat removing and eyesight improving, diuretic relieving constipation, there are laxative action, reducing blood pressure and blood fat.
Radix Puerariae, for the dry root of legume pueraria lobata, practises and claims Herba Gelsemii Elegantis.Autumn, season in winter two excavate, and take advantage of fresh-cut
Sheet or fritter；It is dried.Sweet, pungent, cool.Have an expelling pathogenic factors from muscles for reducing heat, rash, promoting the production of body fluid to quench thirst, yang invigorating antidiarrheal it
Merit.Being usually used in exterior syndrome heating, stiff nape and back, measles without adequate eruption, calentura is thirsty, and the deficiency of YIN is quenched one's thirst, diarrhea of heat type hematodiarrhoea,
Diarrhea due to hypofunction of the spleen.
Semen Phaseoli contain protein, fat, carbohydrate, crude fibre, calcium, phosphorus, ferrum, vitamin B1,
The nutritional labeling such as vitamin B2, saponin.Its nutritive effect: property is put down, sweet in the mouth, acid, energy is inducing diuresis and reducing edema (,
Heat clearing away jaundice eliminating, removing toxic substances and promoting pus discharge.Diuresis is the most useful to heart disease and nephropathy, edematous patient.Rich in leaf
Acid, puerpera, wet nurse eat Semen Ormosiae Hosiei effect of lactogenic.There is good loosening bowel to relieve constipation, blood pressure lowering, fall blood
Fat, regulation blood glucose, prevention calculus, the effect of body building and weight reducing.
Herb Gynostemmae Pentaphylli can blood fat reducing, adjust blood pressure preventing and treating thrombosis, prevent and treat cardiovascular disease, regulate blood glucose, promote to sleep
Sleep, slow aging, anti-anticancer, improve immunity, regulate human physiological functions.Adrenal gland and thymus can be protected
And endocrine organ with the age growth and will not atrophy, maintain the function of hormonal system, and there is fall blood
Sugar and improve carbohydrate metabolism.
Yeast powder can provide organic nitrogen source and the nutrition such as vitamin B complex, auxin for microorganism.
The present invention many employings invigorating the spleen and replenishing QI integration of edible and medicinal herbs raw material, main component Herb Gynostemmae Pentaphylli and Folium Mori be respectively provided with blood pressure lowering,
Reduce blood glucose and blood fat, be simultaneously introduced Semen Phaseoli, Radix Puerariae, Semen Cassiae and yeast powder and rise with main constituent
To synergism, provide necessary nutritional labeling for product of the present invention, make product reduce the same of three-hypers symptom
Time, play the concurrent symptom that balance patient causes because of three-hypers disease.
Formula all uses the extract of conventional commercial simultaneously, eliminates and steam the operation put forward, convenient operation, and
Low cost product in formula, is beneficial to promote.
The present invention drops the test for many years of 3-high health care product and shows, fall three-hypers effect is notable.Stochastic sampling is added up
Result shows, 50 example hyperpietics abide by advise and drink product of the present invention after 60 days, (same period does not take antihypertensive drugs
And other similar health promoting products), have more than 90% the blood pressure of patient have reduction in various degree；60 examples
Diabetics is abided by advise and is drunk product of the present invention after 60 days, (same period does not take hypoglycemic medicine and other similar guarantors
Strong product), have more than 85.0% the blood sugar level of patient have significantly reduction, some patient then returns to
Normal value.
Detailed description of the invention
In order to make those skilled in the art be more fully understood that technical scheme, below in conjunction with
The present invention is described in further detail for good embodiment.
Embodiment 1: take yeast powder 48kg, Folium Mori extract 40kg, Semen Cassiae extract 30kg, Radix Puerariae
Extract kg part, Semen Phaseoli extract 12kg, Herb Gynostemmae Pentaphylli extract 35kg are ground into powder, and cross 80
Mesh sieve, after mixing homogeneously with starch 100kg, with 10% starch slurry soft material, crosses soft material 20 mesh sieves and makes
Wet granular, by wet granular and 60-70 DEG C of drying, the dry granule obtained arranges with 20 mesh sieves, obtains medicine
Granule；The capsule board simultaneously using lucite to support is filled, and first capsule cap, capsule status is opened；Capsule body inserts
In capsule board hole, the distance of regulation levels, make capsule mouth equal with plate face.Granule is laid on plate face,
Vibration capsule board gently, make particles filled uniformly.After filling up each capsule, granule unnecessary for plate face is swept
Remove, jack-up capsule body, set and capsule cap, take out capsule, to obtain final product.
Embodiment 2: yeast powder 48kg, Folium Mori extract 50kg, Semen Cassiae extract 40kg, Radix Puerariae extracts
Thing 11kg, Semen Phaseoli extract 12kg, Herb Gynostemmae Pentaphylli extract 28kg.It is ground into powder, uses pulverizer
120 mesh sieves are crossed standby after pulverizing；By 0.02 part of aspartame of sweeting agent, 0.1 part of sodium alginate of stabilizer is even
Cross 16 mesh stainless (steel) wires after stirring in adding agitator groove with the powder obtained to pelletize, dry,
Powdered agent；
Embodiment 3 is identical with embodiment 2 preparation method, differs only in 1 part of sucralose of sweeting agent, stable
Agent guar gum 1 part.
Embodiment 4 is identical with embodiment 2 preparation method, differs only in containing following content of component: ferment
Female powder 48kg, Folium Mori extract 60kg, Semen Cassiae extract 50kg, Radix Puerariae extract 11kg, red
Semen Phaseoli extract 12kg, Herb Gynostemmae Pentaphylli extract 20kg.
Embodiment 5 is identical with embodiment 2 preparation method, differs only in containing following content of component: female powder
48kg, Folium Mori extract 50kg, Semen Cassiae extract 45kg, Radix Puerariae extract 11kg, Semen Phaseoli extracts
Thing 12kg, Herb Gynostemmae Pentaphylli extract 30kg.
Typical case:
1 Cui, female, 42 years old.Multiple thyroid nodule in 2002.On June 26th, 2006 is diagnosed as
(right side) papillary adenocarcinoma of thyroid.And done operation for the first time.On July 27th, 2002 has done again second
Secondary operation.Afterwards, less than 210 days, its cervical region is along edge of a knife Boss again.Start clothes in March, 2003
With the health product in embodiment 1.One day initial patient felt vexatious and does not feels better, to uncomfortable sense in second day
Feeling and disappear, the tuberosity on the edge of a knife also dies down, and after 15 days, tuberosity all disappears.
2. Liu, man, 65 years old, surpass 10 years diabetic history.Evening on May 21st, 2007 starts to take enforcement
Health product in example 2, to May 28, only seven days, it is soft that patient just feels that abdominal part is shown in, waistline is from original
104 centimetres drop to 91 centimetres, and in abdomen, a large amount of hydrops are discharged, and defecate 23 somatosensories every day energetically
?.Afterwards, patient continues to take 2 months, and the disease of other discomforts such as lower limb fiber crops disappears substantially.Before, patient
Ear shrivelled without voluptuousness,.During to New Year's Day in 2008, helix is full, has rosy cheeks, under hand-holdable spade
Work.
3. Wei, female, 40 years old, deaf mute, familial polycystic kidney disease.2002 3, between April, abdomen
Full pain, uncomfortable in chest calms the anger, and lies awake all night, and health is become thin rapidly.On April 1st, 2002 does ultrasound diagnosis,
The multiple cysts of internal organs such as liver, pancreas, kidney, and with renal calculus.Ultrasound diagnosis on May 1, maximum cyst is
5.1X3.4 centimetre.Start afterwards to take the health product in embodiment 3.After 15 days, pain disappears substantially.
The check of B ultrasonic again on August 5: " its maximum cyst is 4.9X3.4 centimetre, and diagnostic result is " with 5.1 phases
Reduce than maximum cyst.”
4. Xing, female, 77 years old, diabetics.On February 16th, 2002 feels right side of body numbness nothing
Power, is cerebral thrombosis after diagnosing, carries out conventional improvement the most in hospital.Blood item index is recorded for (1) during February 21
Fasting glucose 12.75 mM/ls；(2) HDL1 .51 mM/l；(3) low density lipoprotein
5.40 mM/ls of albumen；(4) atherogenic index LDL/HDL=3.576 (higher).February 22 opened
Beginning to take the health product in embodiment 4, check on May 23rd, 2002 blood item index is (1) fasting glucose
4.327 mM/l；(2) HDL1 .81 mM/l；(3) low density lipoprotein, LDL 5.38
MM/l；(4) atherogenic index LDL/HDL=2.97 (normally).Afterwards, status of patient is the best
Good.
5. what certain, female, 55 years old, certain city Beijing opera performer, diabetics.Cried out because of throat cyst before 20 years
And leave stage, once sought medical advice and had no resolution in many places.In August, 2002 takes the health product in embodiment 2, after 30 days
Physiochemical indice is clearly better, and, after taking only one week, perplex its cyst throat in 20 years and surprisingly cured,
Can act in an opera by sounding again now.
6. state, man, 70 years old.6 years cerebral infarction medical histories of diabetes, double fists can not hold, and two-arm can not swing,
Both hands tremble seriously, and walking ultimate range is 500 meters, and Tianjin hospital expert is diagnosed as " parkinson ".2004
Mid-February in year starts to take the health product in embodiment 2, and to March 25, both hands jitter was the best
Turn.Continuing afterwards to take the health product in embodiment 2, during to May 1, patient can freely hold and hold double fist,
Two-arm also can have swing by a relatively large margin.And, patient can go downstairs under the assisting in not having household voluntarily
Unrivalled go for a trot to 2 Xi Gu parks inside and outside.
7. Zhao, female, 64 years old.Because diabetes cause cerebral thrombosis.Within 2003 10 about 6 days, due to illness focus on sky
Tianjin hospital improves, and a few days state of an illness is not felt any better, it is contemplated that reason determines to go home to recuperate in many ways.October
Taking the health product in embodiment 2 under layman advised on 30th, initial patient feels that right shoulder has pain, 3
Pain disappears in the future, and after 5 days, patient can go out with oneself and get sun.
8. grandson, man, 50 years old.At the beginning of 2003 5 months, feel uncomfortable in chest, calm the anger, abdominal distention, postabdomen swollen
Swollen, it is impossible to feed, to urinate not smooth, night can not fall asleep, costa sternales pain.In May 27 city in 2003
Hospital checks, B ultrasonic diagnoses: 1, early stage liver cirrhosis；2, middle amount ascites.Biochemical investigation: ten indexs
In have 5 severe overweights (i.e. glutamic oxaloacetic transaminase, GOT, albumin, total bilirubin, paddy acyl transpeptidase, alkalescence phosphorus
Acid enzyme).Afterwards, do not take other drug, only take the health product in embodiment 2.After one month, suffer from
Person checks again, B ultrasonic diagnosis on June 30: at present without ascites.Biochemical investigation on June 27: former inspection
In ten indexs tested, glutamic oxaloacetic transaminase, GOT and albumin are the most normal；Other three transnormal itemses (total bilirubin,
Paddy acyl transpeptidase, alkali phosphatase) though the most up to standard, it has been clearly better.Afterwards, Huan Zheji
Continuing and take beverage, to by the end of September, biochemical investigation, index is the most normal.
9. Wang, female, 49 years old, hyperlipidemia patient.Often dizzy, bite and sleep.03 month 15 days calendar year 2001
Having done lectin from hemolymph test in hospital, test result is to have 8 index exceeding standards in 18 indexs, and exceeding standard rate is
44.4%, and qualified rate is only 55.5%.At the beginning of 08 month calendar year 2001, start upon somebody's introduction to take embodiment 2
In health product, after taking 1 month, calendar year 2001 JIUYUE hospital on the 11st has done lectin from hemolymph test again, knot
Fruit is that, in 25 indexs, only 1 exceeds standard, and exceeding standard rate is only 4%, and qualified rate is substantially increased,
Reach 96%.Defect dizzy, that feel sleepy all disappears, and waistline is also decreased obviously with body weight.
10. Liu, man, 62 years old, diabetics.In August, 2013, festering occurs in its right crus of diaphragm instep,
After medicine improves, wound is controlled.On November 14th, 2013, because its left lower limb shank heads on bone side to the left
Occur ulcer, its wound area about 85X70 millimeter, constantly to extravasation protein liquid, suffer from lower limb swelling and
With large stretch of red macule, pain, pruritus are difficult to stand, and limit walking and are in hospital.Period uses physiology salt
Head spore and prostaglandin (being commonly called as cutting stone) carry out venous transfusion and have little effect for two days.Detected blood after the meal that night
Sugar is 25.5.Within 15th, record fasting glucose 17.8.Patient's emotion is irritated.Negotiated, patient is November 16
Start evening day to add to get involved based on the nutrient of the health product in embodiment 2 to improve, second day, i.e. November
17, just solidify at its wound sepage, suffer from lower limb and start detumescence, but red macule is not changed in (continuing
Take the health product series in embodiment 2.To November 22, patient there has been and is clearly better.Affected part week
Limit part incrustation comes off, and suffers from the detumescence of lower limb major part, and red macule starts to disappear, and remains on both feet
There is fold in atropurpureus rough bark, phenomenon of casting off a skin first meeting clue.Fasting glucose is 6.9 8.3, and post-prandial glycemia exists
11.2 between 14.3.We also will continue to pay close attention to the situation of the further rehabilitation of Lao Liu.In November 27
Noon message: fasting glucose is stable 6.4, and post-prandial glycemia is 9.2.During December noon 11 on the 9th 15, personally
The incrustation of the ill leg of be aged Liu the most all comes off, and has new meat to grow, remains in other of lower limb in the past
Ulcer proceeding by property of vestiges is retreated.From the health product nutrient combo starting to take embodiment 2 to visuality
Stage recovers, only 22 days used time.
11, Huang, man, 58 years old, diabetics.2009, because vein blood vessel inflammation is drawn, to make thigh basic
Following large area is festered, and has no resolution through the improvement of time more than nearly 2 years, and has the gesture spreading development, quilt
Tianjin hospital requirements does amputation, and I and family members were the most desperate at that time.Introduce by friend, at knot
While bundle traditional medicine is improved, take the health product in embodiment 2, less than the time of two weeks, fester
Position starts incrustation.Rear stopping medical science being improved, and adheres to taking the health product in embodiment 2, only the most always
With year, being almost recovered, the most original wound also remains light vestige.
12, Mrs Min, 63 years old, cardiac.Between in November, 2006, because diabetic complication causes
Having a heart attack and have a holiday and be in, state of an illness ratio is more serious at that time, sensation of oppression over the chest with shortness of breath, often vomits, repeatedly toilet seat
After stand and fall in a swoon.Examination in hospital is that multiple cardiovascular stalk is stifled, it is proposed that do cardiac stent operation at once.Including
Herself is all weighed down with anxieties to this interior all households.Through friend recommendation, Mrs Min is in early December
Taking the health product in embodiment 2, the time of the only one moon, the health of Mrs Min has had obvious good
Turning, she has rosy cheeks, and two have god,.To examination in hospital after the Spring Festival, cardiovascular has become normal, and hospital makes
There is no need to do the conclusion that cardiac stent is necessary again.At present, Mrs Min is the same with everybody lives normally.
13, temperature certain, man, 82 years old, diabetics.Being in hospital because of heart disease for the end of the year 2015 and improve, the state of an illness is steady
Leave hospital after Ding.But, its right crus of diaphragm instep occurs long 6 centimetres, the exedens wound of wide 4 centimetres, and trickle egg
White liquor is more than, it is impossible to healing, it is impossible to Go to ground activity.Start to take embodiment 2 from January 16th, 2016
In health product, through the time of 45 days, wound was clearly better, by the end of (the phase on March 1st, 2016
Between experienced by the particular time in the Spring Festival), covered with new granulation in wound, the length of wound is by previous
6 centimetres narrow down to 1.5 centimetres, and the wide of wound is narrowed down to present 1 centimetre by original 4 centimetres.3
The moon, its foot's wound of taking pictures for 20th fully recovered.Original face, the edema phenomenon major part in legs and feet portion are moved back
But, now, uncle Wen has been able to Go to ground activity.
14, Zhang, suffers from diabetes for many years, and festering occurs in its right crus of diaphragm lateral heel in the recent period, and topical dermal
Layer is damaged.On June 11st, 2016, damaged location is obvious, and hospital cannot cure.From 2016
June 14 started to take the health product in embodiment 2, and through about 30 days, its wound was clearly better.
The above is only the preferred embodiment of the present invention, it is noted that common for the art
For technical staff, under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications,
These improvements and modifications also should be regarded as protection scope of the present invention.
Claims (5)
1. the health product improving " three-hypers disease ", it is characterised in that containing following content of component:
Yeast powder 48 parts, Folium Mori extract 40-60 part, Semen Cassiae extract 30 50 parts, Radix Puerariae extracts
Thing 11 parts, Semen Phaseoli extract 12 parts, Herb Gynostemmae Pentaphylli extract 20 35 parts.
The health product improving " three-hypers disease " the most according to claim 1, it is characterised in that under containing
State content of component:
Yeast powder 48 parts, Folium Mori extract 50 parts, Semen Cassiae extract 40 parts, Radix Puerariae extract 11 parts,
Semen Phaseoli extract 12 parts, Herb Gynostemmae Pentaphylli extract 28 parts.
3. according to the health product of the improvement " three-hypers disease " described in claims 1 or 2, it is characterised in that
Described each component presses respective formula ratio, makes in hard capsule, tablet, oral solutions, medicinal granules of powder or pill
One.
Preparation the most according to claim 3 improves the health product of " three-hypers disease ", it is characterised in that system
Employing following step during standby hard capsule:
1): be ground into powder after the component of described mass parts being stirred, 80 mesh sieves are crossed, with
After starch mix homogeneously, with 10% starch slurry soft material, soft material is crossed 20 mesh sieves and makes wet granular, by wet
Grain and 60-70 DEG C of drying, the dry granule obtained arranges with 20 mesh sieves, obtains drug particles；
2): the capsule board using lucite to support is filled, and first capsule cap, capsule status is opened；Capsule body inserts glue
In capsule plate holes, the distance of regulation levels, make capsule mouth equal with plate face.By step 1) granule that obtains
Be laid on plate face, vibration capsule board gently, make particles filled uniformly.After filling up each capsule, by plate face
Unnecessary granule cleaning, jack-up capsule body, set and capsule cap, take out capsule, to obtain final product.
Preparation the most according to claim 3 improves the health product of " three-hypers disease ", it is characterised in that system
Employing following step during standby medicinal granules of powder:
1) it is ground into powder after the component of described mass parts being stirred, crosses 120 mesh sieves standby；
2) by sweeting agent 0.02-1 part, stabilizer 0.1～1 part are together with step 1) powder that obtains adds stirring
After stirring in trough cross 16 mesh stainless (steel) wires pelletize, dry, powdered agent；
Described sweeting agent is the one in aspartame, neotame, sucralose, stevioside, acesulfame potassium or several
The mixture planted；Described stabilizer is sodium alginate, xanthan gum, carrageenan, pectin, hydroxylmethyl cellulose
The mixing of one or more in element sodium, guar gum, gellan gum, arabic gum, locust bean gum or chitin
Thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610622457.5A CN105998198B (en) | 2016-07-28 | 2016-07-28 | Health-care product for improving hypertension, hyperglycemia and hyperlipidemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610622457.5A CN105998198B (en) | 2016-07-28 | 2016-07-28 | Health-care product for improving hypertension, hyperglycemia and hyperlipidemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105998198A true CN105998198A (en) | 2016-10-12 |
| CN105998198B CN105998198B (en) | 2020-10-02 |
Family
ID=57134515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610622457.5A Active CN105998198B (en) | 2016-07-28 | 2016-07-28 | Health-care product for improving hypertension, hyperglycemia and hyperlipidemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998198B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114947032A (en) * | 2022-05-17 | 2022-08-30 | 岳小鸥 | A solid beverage for improving blood quality and promoting nutrition balance |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103284038A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Hyperglycemic composition and preparation method thereof |
| CN104027529A (en) * | 2014-06-24 | 2014-09-10 | 贵州遵义华源医药保健品有限公司 | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof |
| CN104083474A (en) * | 2014-07-31 | 2014-10-08 | 史建钢 | Traditional Chinese medicine product for treating gastritis, constipation, hyperlipaemia, hyperglycemia and hypertension |
| CN105661521A (en) * | 2016-01-29 | 2016-06-15 | 仕承生物工程（上海）有限公司 | Composition with functions of reducing hypertension, hyperglycemia and hyperlipidemia and preparation method of composition |
| CN103702677B (en) * | 2013-07-09 | 2016-11-23 | 滕树财 | Three-down Ilex series of health products |
-
2016
- 2016-07-28 CN CN201610622457.5A patent/CN105998198B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103284038A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Hyperglycemic composition and preparation method thereof |
| CN103702677B (en) * | 2013-07-09 | 2016-11-23 | 滕树财 | Three-down Ilex series of health products |
| CN104027529A (en) * | 2014-06-24 | 2014-09-10 | 贵州遵义华源医药保健品有限公司 | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof |
| CN104083474A (en) * | 2014-07-31 | 2014-10-08 | 史建钢 | Traditional Chinese medicine product for treating gastritis, constipation, hyperlipaemia, hyperglycemia and hypertension |
| CN105661521A (en) * | 2016-01-29 | 2016-06-15 | 仕承生物工程（上海）有限公司 | Composition with functions of reducing hypertension, hyperglycemia and hyperlipidemia and preparation method of composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114947032A (en) * | 2022-05-17 | 2022-08-30 | 岳小鸥 | A solid beverage for improving blood quality and promoting nutrition balance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105998198B (en) | 2020-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435775B (en) | A kind of Traditional Chinese medicinal health-care wine and preparation method thereof | |
| CN102907604B (en) | Health-care product having effects of reducing blood sugar and pressure, losing weight, relaxing bowels, maintaining beauty and resisting fatigue and production process thereof | |
| CN102885931B (en) | Traditional Chinese medicine composition for treating abnormal menstruation | |
| CN103478738A (en) | Composite with weight-reducing, body-shaping and weight-controlling functions | |
| CN103405728B (en) | A kind of Chinese medicine composition for the treatment of climacteric syndrome and preparation method thereof | |
| CN103734392A (en) | Fructus cannabis-black tartary buckwheat tea health beverage and preparation method thereof | |
| KR20130063074A (en) | Blood glucose and blood pressure decrease action composition | |
| CN101264255B (en) | Chinese medicinal composition for treating diabetes and preparation thereof | |
| CN106421581A (en) | Biological traditional Chinese medicine for oral administration for treating diabetes and preparation method thereof | |
| CN105998198A (en) | Health product for improving hyperlipidemia, hyperglycemia and hypertension and preparation method thereof | |
| CN101095798B (en) | Chinese traditional medicine for treating canities | |
| CN115120684B (en) | Chinese medicinal composition for treating diabetes and its preparation method | |
| CN101745045B (en) | Food containing Chinese herbal medicines having therapeutic action for diseases of prostate gland | |
| CN107115515A (en) | A kind of Hyperglycemic health care Chinese medicine composition and preparation method thereof | |
| CN108056461B (en) | Black fungus chewable tablet with intestine moistening function and preparation method thereof | |
| CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
| CN104984331A (en) | Solution preparation using biological active multienzyme to restore pancreatic beta-cells and preparation method thereof | |
| CN101002804A (en) | Pure natural preparations used as depressor and hypolipidemic, and preparing method thereof | |
| CN100488519C (en) | Medicine for treating dysmenorrhea and its preparing method | |
| CN101757114A (en) | Hypoglycemic product and preparation method thereof | |
| CN103751558A (en) | Compound blood glucose reducing pills and preparation method thereof | |
| CN113975251B (en) | A Chinese medicinal plaster for treating diabetes and its complications | |
| CN102178870A (en) | Chinese medicinal preparation for promoting qi circulation, promoting blood circulation, softening hard mass and eliminating stagnation for people with qi-depression and phlegm-damp physique, preparation method thereof and application thereof | |
| CN106266427A (en) | A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof | |
| CN103705631B (en) | Gegenjiangtang capsules and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170111 Address after: 108 Wenzhou economic and Technological Development Zone, Zhejiang Binhai Road No. three, room 4699, No. 325024 Applicant after: Wenzhou New Health Biotechnology Co., Ltd. Address before: 300130 Tianjin Binhai New Area, Xinhua Road, Union Village, building, room 2, room 7, 402 Applicant before: Yue Xiaoou |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200911 Address after: Room 202, No. 17-2, Xidiao street, Baiyun District, Guangzhou City, Guangdong Province Applicant after: Guangzhou sadi Biotechnology Co., Ltd Address before: 108 Wenzhou economic and Technological Development Zone, Zhejiang Binhai Road No. three, room 4699, No. 325024 Applicant before: Wenzhou New Health Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right |